التفاصيل البيبلوغرافية
| العنوان: |
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. |
| المؤلفون: |
Neesse, Albrecht, Frese, Kristopher K., Chan, Derek S., Bapiro, Tashinga E., Howat, William J., Richards, Frances M., Ellenrieder, Volker, Jodrell, Duncan I., Tuveson, David A. |
| المصدر: |
Gut; Jun2014, Vol. 63 Issue 6, p974-983, 10p, 5 Graphs |
| مصطلحات موضوعية: |
PHARMACODYNAMICS, DRUG delivery systems, OSTEONECTIN, PACLITAXEL, ANTINEOPLASTIC agents, PHARMACOKINETICS |
| مستخلص: |
Design Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (GEMMs) by liquid chromatography-tandem mass spectrometry (LC-MS/MS), histological and biochemical analysis. Preclinical evaluation of m-nab-paclitaxel included assessment by three-dimensional highresolution ultrasound and molecular analysis in a novel secreted protein acidic and rich in cysteine (SPARC)- deficient GEMM of pancreatic ductal adenocarcinoma (PDA). Results nab-Paclitaxel exerted its antitumoural effects in a dose-dependent manner and was associated with less toxicity compared with cremophor-paclitaxel. SPARC nullizygosity in a GEMM of PDA, KrasG12D;p53flox/-; p48Cre (KPfC), resulted in desmoplastic ductal pancreas tumours with impaired collagen maturation. Paclitaxel concentrations were significantly decreased in SPARC null plasma samples and tissues when administered as low-dose m-nab-paclitaxel. At the maximally tolerated dose, SPARC deficiency did not affect the intratumoural paclitaxel concentration, stromal deposition and the immediate therapeutic response. Conclusions nab-Paclitaxel accumulates and acts in a dose-dependent manner. The interaction of plasma SPARC and albumin-bound drugs is observed at low doses of nab-paclitaxel but is saturated at therapeutic doses in murine tumours. Thus, this study provides important information for future preclinical and clinical trials in PDA using nab-paclitaxel in combination with novel experimental and targeted agents. [ABSTRACT FROM AUTHOR] |
|
Copyright of Gut is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
